Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Aug;24(8):857-858.
doi: 10.1111/hiv.13497. Epub 2023 Apr 24.

Tenofovir alafenamide and weight: What do we still need to know to inform clinical decisions?

Affiliations
Free article
Editorial

Tenofovir alafenamide and weight: What do we still need to know to inform clinical decisions?

Bernard Surial et al. HIV Med. 2023 Aug.
Free article
No abstract available

PubMed Disclaimer

Comment on

References

REFERENCES

    1. Podany AT, Bares SH, Havens J, et al. Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide. Aids. 2018;32(6):761-765.
    1. Surial B, Cavassini M, Calmy A, et al. Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort. BMC Infect Dis. 2019;19(1):834.
    1. Surial B, Mugglin C, Calmy A, et al. Weight and metabolic changes after switching from Tenofovir Disoproxil fumarate to Tenofovir Alafenamide in people living with HIV: a cohort study. Ann Intern Med. 2021;174(6):758-767.
    1. Venter WDF, Moorhouse M, Sokhela S, et al. Dolutegravir plus two different prodrugs of Tenofovir to treat HIV. N Engl J Med. 2019;381(9):803-815.
    1. Hocqueloux L, Menard A, Arvieux C, et al. Weight gain following the single substitution of tenofovir disoproxil fumarate by tenofovir alafenamide in HIV-infected people from the French Dat'AIDS cohort: A propensity score-matched analysis. HIV Med. 2023;24(8):925-932.

MeSH terms

LinkOut - more resources